183 related articles for article (PubMed ID: 14520470)
1. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.
Houston A; Bennett MW; O'Sullivan GC; Shanahan F; O'Connell J
Br J Cancer; 2003 Oct; 89(7):1345-51. PubMed ID: 14520470
[TBL] [Abstract][Full Text] [Related]
2. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
[TBL] [Abstract][Full Text] [Related]
3. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
4. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
5. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
7. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
8. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
9. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Yao H; Song E; Chen J; Hamar P
Br J Cancer; 2004 Nov; 91(9):1718-25. PubMed ID: 15494722
[TBL] [Abstract][Full Text] [Related]
10. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
12. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
15. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC).
Fukuzawa Y; Takahashi K; Furuta K; Tagaya T; Ishikawa T; Wada K; Omoto Y; Koji T; Kakumu S
J Gastroenterol; 2001 Oct; 36(10):681-8. PubMed ID: 11686478
[TBL] [Abstract][Full Text] [Related]
16. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
[TBL] [Abstract][Full Text] [Related]
17. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Kersemaekers AM; van Weeren PC; Oosterhuis JW; Looijenga LH
J Pathol; 2002 Apr; 196(4):423-9. PubMed ID: 11920738
[TBL] [Abstract][Full Text] [Related]
19. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast.
Yakirevich E; Maroun L; Cohen O; Izhak OB; Rennert G; Resnick MB
J Pathol; 2000 Oct; 192(2):166-73. PubMed ID: 11004692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]